JP2022500435A - トリプルネガティブ乳癌の治療のための併用療法 - Google Patents

トリプルネガティブ乳癌の治療のための併用療法 Download PDF

Info

Publication number
JP2022500435A
JP2022500435A JP2021514091A JP2021514091A JP2022500435A JP 2022500435 A JP2022500435 A JP 2022500435A JP 2021514091 A JP2021514091 A JP 2021514091A JP 2021514091 A JP2021514091 A JP 2021514091A JP 2022500435 A JP2022500435 A JP 2022500435A
Authority
JP
Japan
Prior art keywords
compound
breast cancer
subject
inhibitor
brca1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514091A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020053655A5 (https=
JP2022500435A5 (https=
Inventor
エリック・カンポー
ローラ・ツジカワ
サンジャイ・ラコティア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenith Epigenetics Ltd
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of JP2022500435A publication Critical patent/JP2022500435A/ja
Publication of JPWO2020053655A5 publication Critical patent/JPWO2020053655A5/ja
Publication of JP2022500435A5 publication Critical patent/JP2022500435A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021514091A 2018-09-13 2019-09-13 トリプルネガティブ乳癌の治療のための併用療法 Pending JP2022500435A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862730879P 2018-09-13 2018-09-13
US62/730,879 2018-09-13
US201862737628P 2018-09-27 2018-09-27
US62/737,628 2018-09-27
PCT/IB2019/001009 WO2020053655A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of triple-negative breast cancer

Publications (3)

Publication Number Publication Date
JP2022500435A true JP2022500435A (ja) 2022-01-04
JPWO2020053655A5 JPWO2020053655A5 (https=) 2022-09-15
JP2022500435A5 JP2022500435A5 (https=) 2022-09-15

Family

ID=69777478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514091A Pending JP2022500435A (ja) 2018-09-13 2019-09-13 トリプルネガティブ乳癌の治療のための併用療法

Country Status (12)

Country Link
US (1) US11607405B2 (https=)
EP (1) EP3849549A4 (https=)
JP (1) JP2022500435A (https=)
KR (1) KR20210087440A (https=)
CN (1) CN112912077B (https=)
AU (1) AU2019337470A1 (https=)
CA (1) CA3111371A1 (https=)
IL (1) IL281256A (https=)
MX (1) MX2021002886A (https=)
SG (1) SG11202102483SA (https=)
TW (1) TWI816881B (https=)
WO (1) WO2020053655A1 (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN115135984B (zh) 2019-12-23 2025-12-23 10X基因组学有限公司 可逆固定试剂及其使用方法
WO2021133849A1 (en) 2019-12-23 2021-07-01 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
EP4081656A1 (en) 2019-12-23 2022-11-02 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
CN115715329A (zh) 2020-01-10 2023-02-24 10X基因组学有限公司 确定生物样品中靶核酸位置的方法
US12365942B2 (en) 2020-01-13 2025-07-22 10X Genomics, Inc. Methods of decreasing background on a spatial array
US12405264B2 (en) 2020-01-17 2025-09-02 10X Genomics, Inc. Electrophoretic system and method for analyte capture
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
ES2965354T3 (es) 2020-04-22 2024-04-12 10X Genomics Inc Métodos para análisis espacial que usan eliminación de ARN elegido como diana
CN116134308B (zh) 2020-05-19 2025-05-27 10X基因组学有限公司 电泳盒和仪器
EP4553168A3 (en) 2020-05-22 2025-08-27 10x Genomics, Inc. Spatial analysis to detect sequence variants
EP4153775B1 (en) 2020-05-22 2024-07-24 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021237056A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Rna integrity analysis in a biological sample
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
EP4025692A2 (en) 2020-06-02 2022-07-13 10X Genomics, Inc. Nucleic acid library methods
EP4158054B1 (en) 2020-06-02 2025-04-16 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US12435363B1 (en) 2020-06-10 2025-10-07 10X Genomics, Inc. Materials and methods for spatial transcriptomics
US20230279474A1 (en) 2020-06-10 2023-09-07 10X Genomics, Inc. Methods for spatial analysis using blocker oligonucleotides
EP4165207B1 (en) 2020-06-10 2024-09-25 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021252747A1 (en) 2020-06-10 2021-12-16 1Ox Genomics, Inc. Fluid delivery methods
EP4172362B1 (en) 2020-06-25 2024-09-18 10X Genomics, Inc. Spatial analysis of dna methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US12209280B1 (en) 2020-07-06 2025-01-28 10X Genomics, Inc. Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US20230287475A1 (en) 2020-07-31 2023-09-14 10X Genomics, Inc. De-crosslinking compounds and methods of use for spatial analysis
US12553898B1 (en) 2020-08-10 2026-02-17 10X Genomics, Inc. Fluorescent hybridization of antibody-oligonucleotide for multiplexing and signal amplification
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
EP4530358A3 (en) 2020-09-15 2025-06-18 10x Genomics, Inc. Methods of releasing an extended capture probe from a substrate and uses of the same
AU2021345133A1 (en) 2020-09-16 2023-03-30 10X Genomics, Inc. Methods of determining the location of an analyte in a biological sample using a plurality of wells
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
AU2021385065A1 (en) 2020-11-18 2023-06-15 10X Genomics, Inc. Methods and compositions for analyzing immune infiltration in cancer stroma to predict clinical outcome
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
EP4729631A2 (en) 2020-12-21 2026-04-22 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2022147005A1 (en) 2020-12-30 2022-07-07 10X Genomics, Inc. Methods for analyte capture determination
US20240093290A1 (en) 2021-01-29 2024-03-21 10X Genomics, Inc. Method for transposase mediated spatial tagging and analyzing genomic dna in a biological sample
ES3008686T3 (en) 2021-03-18 2025-03-24 10X Genomics Inc Multiplex capture of gene and protein expression from a biological sample
WO2022226057A1 (en) 2021-04-20 2022-10-27 10X Genomics, Inc. Methods for assessing sample quality prior to spatial analysis using templated ligation
EP4320271B1 (en) 2021-05-06 2025-03-19 10X Genomics, Inc. Methods for increasing resolution of spatial analysis
EP4582555A3 (en) 2021-06-03 2025-10-22 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
US20240368711A1 (en) 2021-06-22 2024-11-07 10X Genomics, Inc. Spatial detection of sars-cov-2 using templated ligation
EP4352252B1 (en) 2021-07-13 2026-01-28 10X Genomics, Inc. Methods for spatial analysis using targeted probe silencing
US12553805B2 (en) 2021-08-02 2026-02-17 10X Genomics, Inc. Methods of preserving a biological sample
WO2023018799A1 (en) 2021-08-12 2023-02-16 10X Genomics, Inc. Methods, compositions and systems for identifying antigen-binding molecules
ES3011462T3 (en) 2021-09-01 2025-04-07 10X Genomics Inc Methods for blocking a capture probe on a spatial array
TW202327594A (zh) * 2021-09-23 2023-07-16 大陸商恒翼生物醫藥（上海）股份有限公司 用ｂｅｔ溴結構域抑制劑和ｐａｒｐ抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
WO2023086880A1 (en) 2021-11-10 2023-05-19 10X Genomics, Inc. Methods, compositions, and kits for determining the location of an analyte in a biological sample
WO2023102313A1 (en) 2021-11-30 2023-06-08 10X Genomics, Inc. Systems and methods for identifying regions of aneuploidy in a tissue
EP4305195A2 (en) 2021-12-01 2024-01-17 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
WO2023150171A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from glioblastoma samples
WO2023150163A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from lymphatic tissue
EP4479933A1 (en) 2022-02-15 2024-12-25 10x Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
WO2023215552A1 (en) 2022-05-06 2023-11-09 10X Genomics, Inc. Molecular barcode readers for analyte detection
WO2023229982A2 (en) 2022-05-24 2023-11-30 10X Genomics, Inc. Porous structure confinement for convection suppression
WO2023250077A1 (en) 2022-06-22 2023-12-28 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2024035844A1 (en) 2022-08-12 2024-02-15 10X Genomics, Inc. Methods for reducing capture of analytes
EP4573208A1 (en) 2022-10-10 2025-06-25 10X Genomics, Inc. In vitro transcription of spatially captured nucleic acids
WO2024086167A2 (en) 2022-10-17 2024-04-25 10X Genomics, Inc. Methods, compositions, and kits for determining the location of an analyte in a biological sample
WO2024102809A1 (en) 2022-11-09 2024-05-16 10X Genomics, Inc. Methods, compositions, and kits for determining the location of multiple analytes in a biological sample
WO2024145441A1 (en) 2022-12-29 2024-07-04 10X Genomics, Inc. Methods, compositions, and kits for determining a location of a target nucleic acid in a fixed biological sample
EP4486913B1 (en) 2022-12-30 2025-07-16 10x Genomics, Inc. Methods, compositions, and kits for multiple barcoding and/or high-density spatial barcoding
WO2024145445A1 (en) 2022-12-30 2024-07-04 10X Genomics, Inc. Methods of capturing target analytes
EP4689174A1 (en) 2023-03-28 2026-02-11 10X Genomics, Inc. Methods, compositions, and kits for reducing analyte mislocalization
US20250257393A1 (en) 2023-04-21 2025-08-14 10X Genomics, Inc. Methods and compositions for detecting nucleic acids in a fixed biological sample
WO2024238900A1 (en) 2023-05-17 2024-11-21 10X Genomics, Inc. Methods of reducing mislocalization of an analyte
WO2024254316A1 (en) 2023-06-07 2024-12-12 10X Genomics, Inc. Compositions and methods for identifying blood clots in biological samples
EP4728062A1 (en) 2023-06-13 2026-04-22 10X Genomics, Inc. Sequence specific dna binding proteins
WO2025029605A1 (en) 2023-07-28 2025-02-06 10X Genomics, Inc. Methods and compositions for detecting genetic variants using capture probes and primer extension
WO2025029627A1 (en) 2023-07-31 2025-02-06 10X Genomics, Inc. Methods, compositions, and kits for spatial detection of genetic variants
EP4581160A1 (en) 2023-08-24 2025-07-09 10X Genomics, Inc. Methods, kits, and compositions for spatial detection of genetic variants
WO2025064893A1 (en) * 2023-09-20 2025-03-27 The Trustees Of Columbia University In The City Of New York Methods of reversing parp-resistance in cancer
WO2025072119A1 (en) 2023-09-26 2025-04-03 10X Genomics, Inc. Methods, compositions, and kits for detecting spatial chromosomal interactions
WO2025090912A1 (en) 2023-10-26 2025-05-01 10X Genomics, Inc. Spatial arrays containing reusable master probes
WO2025096581A1 (en) 2023-10-31 2025-05-08 10X Genomics, Inc. Methods of spatial analysis and single nuclei sequencing
WO2025101864A1 (en) 2023-11-09 2025-05-15 10X Genomics, Inc. Methods, compositions, and kits for reducing mislocalization of analytes in spatial analysis assays
WO2025101377A1 (en) 2023-11-09 2025-05-15 10X Genomics, Inc. Matrix-assisted spatial analysis of biological samples
WO2025255457A1 (en) 2024-06-07 2025-12-11 10X Genomics, Inc. Compositions and methods for improved on-target spatial profiling
WO2026024934A1 (en) 2024-07-25 2026-01-29 10X Genomics, Inc. Methods, compositions, and kits for spatial analysis by tagmentation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523259A (ja) * 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． 新規の二環式ブロモドメイン阻害剤
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2017059319A2 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004246A (es) * 2007-10-18 2010-04-30 Novartis Ag Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas.
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
WO2014128655A1 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
JP2017503771A (ja) * 2013-12-10 2017-02-02 アッヴィ・インコーポレイテッド トリプルネガティブ乳癌を治療するためのベリパリブとカルボプラチンの組合せ
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523259A (ja) * 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． 新規の二環式ブロモドメイン阻害剤
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
WO2017015027A1 (en) * 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2017059319A2 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 78(4_Supplement), JPN6023034130, February 2018 (2018-02-01), pages 1 - 14, ISSN: 0005285819 *
CLIN CANCER RES, vol. 23(14), JPN6023034133, 2017, pages 3711 - 3720, ISSN: 0005285822 *
ONCOTARGET, vol. 8(41), JPN6023034132, 2017, pages 71285 - 71291, ISSN: 0005285821 *
PHARMACOL RES., vol. 129, JPN6023034129, March 2018 (2018-03-01), pages 156 - 176, ISSN: 0005285818 *
PNAS, vol. 115(21), JPN6023034131, 2018, pages 5534 - 5539, ISSN: 0005285820 *
SCI TRANSL MED., vol. 9(400), JPN6023034128, 2017, ISSN: 0005285817 *

Also Published As

Publication number Publication date
WO2020053655A1 (en) 2020-03-19
US11607405B2 (en) 2023-03-21
MX2021002886A (es) 2021-07-15
EP3849549A4 (en) 2022-06-08
EP3849549A1 (en) 2021-07-21
TWI816881B (zh) 2023-10-01
SG11202102483SA (en) 2021-04-29
US20220062246A1 (en) 2022-03-03
IL281256A (en) 2021-04-29
CN112912077B (zh) 2023-04-04
AU2019337470A1 (en) 2021-03-25
CN112912077A (zh) 2021-06-04
KR20210087440A (ko) 2021-07-12
TW202027746A (zh) 2020-08-01
CA3111371A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
JP2022500435A (ja) トリプルネガティブ乳癌の治療のための併用療法
CN112920176B (zh) 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
CN107531683B (zh) Usp7抑制剂化合物及使用方法
TWI874925B (zh) 癌症治療
KR20200062386A (ko) 암 치료용 병용 요법
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
WO2010139180A1 (zh) 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
JP2022519237A (ja) Ｄｎａポリメラーゼシータ阻害剤としてのアセトアミド誘導体
TW201331182A (zh) 抗腫瘤劑之效果增強劑
JP7241134B2 (ja) Ｂｃｌ－３阻害剤としての２－ベンゾイルアミノベンズアミド誘導体
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2014363935A1 (en) Small molecule c-Myc inhibitors
JP2009533472A (ja) 癌治療法
JP7441214B2 (ja) 前立腺がんの治療のための併用療法
JP2022521173A (ja) 癌治療
CN115583938A (zh) 靶向BCL9/β-连环蛋白互相作用的小分子化合物
JP2021527071A (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３−ｂ］ピリジン誘導体及びその医薬用途
WO2024137751A1 (en) Methods of treating advanced solid tumors
EP3849550B1 (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
CN116751161A (zh) 喹啉类化合物及其制备方法、药物组合物及医药用途
EP4154890A1 (en) Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
EA043826B1 (ru) Комбинированная терапия для лечения трижды негативного рака молочной железы
HK40054127A (en) Combination therapy for the treatment of triple-negative breast cancer
KR20250121036A (ko) 나프타미드계 화합물, 이의 제조방법 및 응용
TW202327594A (zh) 用ｂｅｔ溴結構域抑制劑和ｐａｒｐ抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240319